SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today announced the pricing of its initial public offering of 9,375,000 shares of
Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical development of an autologous iPSC-derived neuron replacement therapy for Parkinson’s disease, now entering Phase 3 SAN DIEGO, Sept.
SAN DIEGO, July 30, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s
Advancement of commercial-ready formulation supports scalability and late-stage development SAN DIEGO, June 30, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced completion
Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life This Personalized Autologous Cell Therapy Aims to Replace and Restore the Damaged Neural Circuitry in Parkinson’s
Approved for Use By both the World Health Organization’s International Nonproprietary Names (WHO-INN) and the American Medical Association’s United States Adopted Names (AMA-USAN) Council SAN DIEGO, Mar. 12, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company
Facility Enters Qualification to Support Late‑Stage Pivotal Manufacturing and Commercial Readiness SAN DIEGO, Jan. 8, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced completion of Cohort
